NASDAQ:SGMO Sangamo Therapeutics - SGMO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.66 -0.04 (-2.35%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.60▼$1.6950-Day Range$1.66▼$3.6752-Week Range$1.58▼$6.42Volume1.46 million shsAverage Volume2.50 million shsMarket Capitalization$279.68 millionP/E RatioN/ADividend YieldN/APrice Target$13.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Sangamo Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside733.3% Upside$13.83 Price TargetShort InterestBearish9.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.29) to ($1.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector303rd out of 1,005 stocksBiological Products, Except Diagnostic Industry51st out of 168 stocks 4.4 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.83, Sangamo Therapeutics has a forecasted upside of 733.3% from its current price of $1.66.Amount of Analyst CoverageSangamo Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.02% of the float of Sangamo Therapeutics has been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Sangamo Therapeutics has recently increased by 2.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMO. Previous Next 3.0 News and Social Media Coverage News SentimentSangamo Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sangamo Therapeutics this week, compared to 1 article on an average week.Search Interest15 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.MarketBeat Follows4 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($1.29) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sangamo Therapeutics (NASDAQ:SGMO) StockSangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.Read More Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comBrokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $13.83March 21, 2023 | finance.yahoo.comSangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 20, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO)March 10, 2023 | finance.yahoo.comSangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 6, 2023 | bizjournals.comBiotechs reach for the shelf for flexibility in raising more cashMarch 3, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Sangamo TherapeuticsFebruary 27, 2023 | msn.comSangamo gains 11% as Wedbush upgrades on Fabry disease candidateMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 25, 2023 | finance.yahoo.comIn the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actionsFebruary 24, 2023 | seekingalpha.comSangamo Therapeutics, Inc. (SGMO) Q4 2022 Earnings Call TranscriptFebruary 23, 2023 | finance.yahoo.comSangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical BenefitFebruary 22, 2023 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue EstimatesFebruary 22, 2023 | finance.yahoo.comSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial ResultsFebruary 22, 2023 | finance.yahoo.comHere's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 WeeksFebruary 21, 2023 | msn.comEarnings Preview For Sangamo TherapeuticsFebruary 21, 2023 | finance.yahoo.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and WebcastFebruary 16, 2023 | finance.yahoo.comSangamo Therapeutics (SGMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?February 13, 2023 | finance.yahoo.comHere's Why Sangamo (SGMO) Looks Ripe for Bottom FishingJanuary 6, 2023 | investing.comBofA Securities Downgrades Sangamo BioSciences to NeutralDecember 13, 2022 | markets.businessinsider.comWedbush Keeps Their Hold Rating on Sangamo Biosciences (SGMO)December 6, 2022 | finance.yahoo.comSangamo Therapeutics (NASDAQ:SGMO) investors are sitting on a loss of 78% if they invested five years agoNovember 9, 2022 | finance.yahoo.comSangamo Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 4, 2022 | finance.yahoo.comSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial ResultsNovember 4, 2022 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue EstimatesNovember 2, 2022 | msn.comSangamo Therapeutics's Earnings OutlookOctober 31, 2022 | fool.comSangamo Therapeutics (NASDAQ: SGMO)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Company Calendar Last Earnings2/22/2023Today3/26/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees431Year Founded1995Price Target and Rating Average Stock Price Forecast$13.83 High Stock Price Forecast$19.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+733.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,280,000.00 Net Margins-172.76% Pretax Margin-172.37% Return on Equity-61.19% Return on Assets-31.68% Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio2.69 Sales & Book Value Annual Sales$111.30 million Price / Sales2.51 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.92Miscellaneous Outstanding Shares168,480,000Free Float164,945,000Market Cap$279.68 million OptionableOptionable Beta1.17 Social Links Key ExecutivesAlexander D. MacraePresident, Chief Executive Officer & DirectorMark D. McClungChief Operating Officer & Executive Vice PresidentPrathyusha DurabaibuSenior VP, Chief Financial & Accounting OfficerR. Andrew RamelmeierExecutive Vice President-Technical OperationsJason D. FontenotChief Scientific Officer & Senior Vice PresidentKey CompetitorsNovavaxNASDAQ:NVAXAgenusNASDAQ:AGENDBV TechnologiesNASDAQ:DBVTHumacyteNASDAQ:HUMAAtara BiotherapeuticsNASDAQ:ATRAView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 11,761 shares on 3/23/2023Ownership: 0.033%Alliancebernstein L.P.Bought 200,000 shares on 2/16/2023Ownership: 0.215%Legal & General Group PlcBought 3,744 shares on 2/15/2023Ownership: 0.036%MetLife Investment Management LLCSold 11,761 shares on 2/15/2023Ownership: 0.034%E Fund Management Co. Ltd.Bought 9,284 shares on 2/15/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions SGMO Stock - Frequently Asked Questions Should I buy or sell Sangamo Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGMO shares. View SGMO analyst ratings or view top-rated stocks. What is Sangamo Therapeutics' stock price forecast for 2023? 6 Wall Street analysts have issued 12 month price targets for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $5.00 to $19.00. On average, they predict the company's stock price to reach $13.83 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price. View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts. How have SGMO shares performed in 2023? Sangamo Therapeutics' stock was trading at $3.14 at the beginning of 2023. Since then, SGMO shares have decreased by 47.1% and is now trading at $1.66. View the best growth stocks for 2023 here. When is Sangamo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our SGMO earnings forecast. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings data on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.04. The biopharmaceutical company had revenue of $27.23 million for the quarter, compared to analysts' expectations of $26.86 million. Sangamo Therapeutics had a negative net margin of 172.76% and a negative trailing twelve-month return on equity of 61.19%. The business's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company posted ($0.26) EPS. What ETFs hold Sangamo Therapeutics' stock? ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Direxion mRNA ETF (MSGR), Kelly CRISPR & Gene Editing Technology ETF (XDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI). What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO? 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC). What is Sangamo Therapeutics' stock symbol? Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO." Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Credit Suisse AG (2.32%), Dimensional Fund Advisors LP (2.10%), Avidity Partners Management LP (1.68%), Geode Capital Management LLC (1.52%), Renaissance Technologies LLC (1.29%) and JPMorgan Chase & Co. (0.95%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry. View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sangamo Therapeutics' stock price today? One share of SGMO stock can currently be purchased for approximately $1.66. How much money does Sangamo Therapeutics make? Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $279.68 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. How many employees does Sangamo Therapeutics have? The company employs 431 workers across the globe. How can I contact Sangamo Therapeutics? Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951. This page (NASDAQ:SGMO) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.